Biogen Gets EU Panel OK for MS Drug

Xconomy Boston — 

Weston, MA-based Biogen Idec (NASDAQ: BIIB) said today that it has received a positive opinion from a committee of the European Medicines Agency, which should pave the way to begin sales in Europe of fampridine (Fampyra) as a new treatment for multiple sclerosis. Based on the committee recommendation, Biogen Idec said it expects to be cleared to begin sales within 67 days. Hawthorne, NY-based Acorda Therapeutics (NASDAQ: ACOR) developed the drug, sells it in the U.S., and granted Biogen a license to commercialize the product outside the U.S.